Novo Nordisk
NVO
$157.53
Share price
-2.01%
Change (1 day)
35.95%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Revenue for Novo Nordisk (NVO)
Revenue in 2023 (TTM): $26.55 B
According to Novo Nordisk's latest financial reports the company's current revenue (TTM) is $26.55 B. In 2022 the company made a revenue of $25.05 B an increase over the years 2021 revenue that were of $22.01 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novo Nordisk from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $26.55 B | 6.01% |
| 2022 | $25.05 B | 13.81% |
| 2021 | $22.01 B | 11.61% |
| 2020 | $19.72 B | 7.92% |
| 2019 | $18.27 B | 3.71% |
| 2018 | $17.62 B | 2.27% |
| 2017 | $17.22 B | 3.93% |
| 2016 | $16.57 B | 3.64% |
| 2015 | $15.99 B | 3.1% |
| 2014 | $15.51 B | 4.18% |
| 2013 | $14.89 B | 9.28% |
| 2012 | $13.62 B | 11.19% |
| 2011 | $12.25 B | 14.14% |
| 2010 | $10.73 B | 11.21% |
| 2009 | $9.65 B | 6.07% |
| 2008 | $9.10 B | 15.82% |
| 2007 | $7.85 B | 18.71% |
| 2006 | $6.62 B | 20.12% |
| 2005 | $5.51 B | 12.16% |
| 2004 | $4.91 B | 16.3% |
| 2003 | $4.22 B | 20.24% |
| 2002 | $3.51 B | 0.74% |
| 2001 | $3.48 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $92.95 B | 250.02% | 🇺🇸 USA |
 Eli Lilly LLY | $27.69 B | 4.28% | 🇺🇸 USA |
 Sanofi SNY | $48.25 B | 81.69% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | $45.84 B | 72.65% | 🇺🇸 USA |